HKAM
AKBA icon

Horizon Kinetics Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Horizon Kinetics Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-32,133
Closed -$126K – 477
2019
Q3 		$126K Hold
32,133
– – ﹤0.01% 467
2019
Q2 		$156K Sell
32,133
-33,299
-51% -$189K ﹤0.01% 471
2019
Q1 		$536K Buy
+65,432
New +$449K 0.01% 253

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Horizon Kinetics Asset Management's AKBA Position: Q4 2019 in Review

Horizon Kinetics Asset Management sold out of Akebia Therapeutics (AKBA) in Q4 2019, closing a stake of 32,133 shares — an estimated $126K sold.

Horizon Kinetics Asset Management first reported a position in AKBA in Q1 2019 and held it in 3 quarters. The position peaked at $536K in Q1 2019. 153 funds tracked by Wall St. Rank hold AKBA as of Q4 2019.

  • Horizon Kinetics Asset Management reported no remaining Akebia Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Horizon Kinetics Asset Management sold 32,133 Akebia Therapeutics shares in Q4 2019, an estimated $126K.
  • Horizon Kinetics Asset Management first reported a position in Akebia Therapeutics in Q1 2019 and held it in 3 quarters.
  • Horizon Kinetics Asset Management's Akebia Therapeutics position peaked at $536K in Q1 2019.
  • 153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2019.

Based on Horizon Kinetics Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.